Pharmaceuticals

CMC considerations for US biosimilars development

By , , 2022-04-18T15:18:00

AdobeStock_281211016

Source: Adobe Stock

The US Biologics Price Competition and Innovation Act of 2009 (BPCI Act) provides an abbreviated licensure pathway for biosimilar products. This pathway brought the hope of lower cost biologics, perhaps similar to what was accomplished by generics for small molecule drugs. Twelve years have now passed since the BPCI Act and experience continues to be gained with biosimilars development… 

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.

 

Not a TOPRA member yet? Join our global community before
30 September and get 3 month’s extra membership for only £20.

Join by 30 September to get this exclusive rate.

Five great reasons to become a TOPRA member:

  1. Great savings on our events and training.
  2. Be part of our dynamic international community.
  3. Contribute to the profession.
  4. Grow your skills and knowledge.
  5. Take your career to the next level.

Become a member today!

Have you heard? Why not listen to one of our free podcasts to see what you’re missing?